These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35029303)

  • 1. COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
    Sun C
    Br J Haematol; 2022 Apr; 197(1):11-12. PubMed ID: 35029303
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Ujjani C; Shadman M; Lynch RC; Tu B; Stevenson PA; Grainger C; Zhu H; Hill JA; Huang ML; Nielsen L; Poh C; Sorensen T; Gopal AK; Warren EH; Till BG; Lee S; Gausman D; Smith SD; Gooley T; Greninger A
    Br J Haematol; 2022 May; 197(3):306-309. PubMed ID: 35149986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
    Mehta-Shah N; Bartlett NL; Kahl B; Watkins MP; Dubois A; Schmelzle G; Waqar S; Ballman C; Wan F; Farnsworth CW
    Leuk Lymphoma; 2022 Jul; 63(7):1723-1727. PubMed ID: 35225130
    [No Abstract]   [Full Text] [Related]  

  • 4. SARS-CoV-2 vaccination in CLL: how often is enough?
    Mellinghoff SC; Cornely OA
    Blood; 2022 Dec; 140(25):2655-2657. PubMed ID: 36548017
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
    Sorcini D; De Falco F; Gargaro M; Bozza S; Guarente V; Cardinali V; Stella A; Adamo FM; Silva Barcelos EC; Rompietti C; Dorillo E; Geraci C; Esposito A; Arcaleni R; Capoccia S; Mameli MG; Graziani A; Moretti L; Cipiciani A; Riccardi C; Mencacci A; Fallarino F; Rosati E; Sportoletti P
    Br J Haematol; 2023 Apr; 201(1):45-57. PubMed ID: 36484163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
    Diamantopoulos PT; Kontandreopoulou CN; Stafylidis C; Vlachopoulou D; Giannakopoulou N; Vardaka M; Mpouhla A; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
    Ann Hematol; 2022 Dec; 101(12):2711-2717. PubMed ID: 36271935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
    Del Poeta G; Laureana R; Bomben R; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Nunzi A; Postorino M; Pasqualone G; Brisotto G; Steffan A; Muraro E; Zucchetto A; Del Principe MI; Gattei V
    Hematol Oncol; 2023 Aug; 41(3):559-562. PubMed ID: 36585917
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
    Morawska M
    Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Shen Y; Freeman JA; Holland J; Solterbeck A; Naidu K; Soosapilla A; Downe P; Tang C; Kerridge I; Wallman L; Van Bilsen N; Milogiannakis V; Akerman A; Martins Costa Gomes G; Sandgren K; Cunningham AL; Turville S; Mulligan SP
    Br J Haematol; 2022 Apr; 197(1):41-51. PubMed ID: 34962656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination efficacy in patients with chronic lymphocytic leukemia.
    Wang KY; Shah P; Skavla B; Fayaaz F; Chi J; Rhodes JM
    Leuk Lymphoma; 2023 Jan; 64(1):42-56. PubMed ID: 36270021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
    Avivi I; Luttwak E; Saiag E; Halperin T; Haberman S; Sarig A; Levi S; Aharon A; Herishanu Y; Perry C
    Br J Haematol; 2022 Mar; 196(6):1329-1333. PubMed ID: 35075635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia.
    Parry H; Bruton R; Roberts T; McIlroy G; Damery S; Sylla P; Dowell AC; Tut G; Lancaster T; Bone D; Willett B; Logan N; Scott S; Hulme S; Jadir A; Amin U; Nicol S; Stephens C; Faustini S; Al-Taei S; Richter A; Blakeway D; Verma K; Margielewska-Davies S; Pearce H; Pratt G; Zuo J; Paneesha S; Moss P
    Cancer Cell; 2022 Jun; 40(6):584-586. PubMed ID: 35588735
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-spike antibody response to the COVID vaccine in lymphoma patients.
    Della Pia A; Kim GYG; Ip A; Ahn J; Liu Y; Kats S; Koropsak M; Lukasik B; Contractor A; Amin K; Ayyagari L; Zhao C; Gupta A; Batistick M; Leslie LA; Goy AH; Feldman TA
    PLoS One; 2022; 17(12):e0266584. PubMed ID: 36454941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
    Molica S; Tam C; Polliack A
    Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
    Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
    Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
    Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
    BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
    Schenker C; Hirzel C; Walti LN; Zeerleder SS; Andres M; Ramette A; Barbani MT; Suter-Riniker F; Holbro A; Tritschler T
    Br J Haematol; 2022 Feb; 196(3):e27-e29. PubMed ID: 34458995
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Mellinghoff SC; Mayer L; Robrecht S; Weskamm LM; Dahlke C; Gruell H; Schlotz M; Vanshylla K; Schloser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
    Haematologica; 2022 Oct; 107(10):2480-2484. PubMed ID: 35734927
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
    Cuneo A; Rigolin GM; Coscia M; Quaresmini G; Scarfò L; Mauro FR; Motta M; Quaglia FM; Trentin L; Ferrario A; Laurenti L; Reda G; Ferrari A; Pietrasanta D; Sportoletti P; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; Farina L; Del Poeta G; Varettoni M; Chiurazzi F; Marasca R; Malerba L; Ibatici A; Tisi MC; Stefoni V; Leone M; Baratè C; Olivieri J; Murru R; Gentile M; Sanna A; Gozzetti A; Gattei V; Gottardi D; Derenzini E; Levato L; Orsucci L; Penna G; Chiarenza A; Foà R
    Hematol Oncol; 2021 Oct; 39(4):570-574. PubMed ID: 34258787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.